SYDRA AG

Using AI and in vivo screens to develop novel geroprotectors

SYDRA is a Biotech startup developing preclinical drug candidates for age-associated diseases using a proprietary AI-driven, phenotype-first approach (Hit-to-Target method). We combine AI-powered novel compound discovery with in vivo validation in C. elegans and elderly rodents to identify geroprotectors that extend healthspan and lifespan. Successful candidates enter the drug development pipeline for pharmaceutical licensing (B2B), while naturally safe non-patentable compounds (alike: NMN, Urolithin, creatine, etc) will advance into the consumer longevity supplements market (B2C). Our dual revenue model, AI-driven efficiency, and focus on validated in vivo effects position SYDRA as a disruptor in the growing $27 trillion longevity market.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

No news

No milestones

No Jobs

No videos and documents

Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Venture Kick (10'000) 2023

Website